LCM
VYGR icon

Laurion Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Laurion Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-355,950
Closed -$6.96M – 1568
2018
Q2 		$6.96M Buy
355,950
+66,987
+23% +$1.32M 0.06% 287
2018
Q1 		$5.43M Sell
288,963
-173,942
-38% -$3.76M 0.04% 347
2017
Q4 		$7.68M Buy
+462,905
New +$7.94M 0.04% 402

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Laurion Capital Management's VYGR Position: Q3 2018 in Review

Laurion Capital Management sold out of Voyager Therapeutics (VYGR) in Q3 2018, closing a stake of 355,950 shares — an estimated $6.96M sold.

Laurion Capital Management first reported a position in VYGR in Q4 2017 and held it in 3 quarters. The position peaked at $7.68M in Q4 2017. 119 funds tracked by Wall St. Rank hold VYGR as of Q3 2018.

  • Laurion Capital Management reported no remaining Voyager Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Laurion Capital Management sold 355,950 Voyager Therapeutics shares in Q3 2018, an estimated $6.96M.
  • Laurion Capital Management first reported a position in Voyager Therapeutics in Q4 2017 and held it in 3 quarters.
  • Laurion Capital Management's Voyager Therapeutics position peaked at $7.68M in Q4 2017.
  • 119 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2018.

Based on Laurion Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.